{"database": "lobbying", "table": "lobbying_activities", "rows": [[2308845, "1469c469-0373-45aa-83a1-8aba36486974", "Q2", "EMERGENT BIOSOLUTIONS INC.", 304931, "EMERGENT BIOSOLUTIONS INC", 2019, "second_quarter", "DIS", "FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government\n Re-authorization of the Pandemic and All-Hazards Preparedness Act\n NDAA - provisions related to biological and chemical defense\n Department of Defense appropriations for Medical Countermeasures\n FDA regulatory issues\n Issues related to Priority Review Voucher programs\n Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines", "HOUSE OF REPRESENTATIVES,SENATE", null, 740000, 0, 0, "2019-07-18T09:31:05.780000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2308845"], "units": {}, "query_ms": 0.32147200545296073, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}